Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Marimed Inc.

OTC: MRMD · Life Sciences · 4 alerts · CIK 1522767

Share price
$0.0626Close, Nov 16
Market cap
$25.4M
Shares outstanding
406MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Marimed Inc. filings on SEC EDGAR ↗

6:01 AM ET 10-Q
Financial Results

Marimed Q3 2026 Results: Net Loss of $3.5M, Loss Widens

MariMed Inc. reported revenue of $44.2 million for the third quarter of 2026, a 9% increase year-over-year, though it recorded a net loss of $3.5 million due to high income tax provisions and interest expenses. The company's balance sheet shows $10.4 million in cash and a total of 405,996,010 common shares outstanding as of November 10, 2026.

Key figure
Net loss $3.5M
6:10 AM ET 8-K
Financial Results

Marimed Financial Results

MariMed Inc. reported record third-quarter 2026 revenue of $44.2 million, a year-over-year increase driven by growth in both wholesale and retail segments. Despite the revenue growth, the company reported a GAAP net loss of $3.5 million as it continues to execute its 'Expand the Brand' strategy and navigate broader market conditions.

Term
Q3 2026

“I’m pleased to report that the momentum we built earlier this year extended through the third quarter. Wholesale and retail revenue both grew sequentially and year over year, and total revenue reached another record for MariMed. Adjusted EBITDA improved from the prior quarter, and we again generated positive cash flow from operations, ending the quarter in our strongest position in more than two years.”

Jon Levine, MariMed’s Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.